2026 Global: Cell Reprogramming-Competitive Review (2032) report
Description
The 2026 Global: Cell Reprogramming-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell reprogramming by geography and historical trend. The scope of the report extends to sizing of the cell reprogramming market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Thermo Fisher Scientific, Lonza, Merck KGaA (MilliporeSigma), FUJIFILM Cellular Dynamics, STEMCELL Technologies, REPROCELL, Bio-Techne, Mogrify, Fate Therapeutics, and Takara Bio represent ten major companies active in cell reprogramming, each supplying critical products, platforms, or therapeutic pipelines that shape the field. Thermo Fisher offers broad reagent, instrument, and platform portfolios used in reprogramming research and manufacturing. Lonza provides large-scale manufacturing, media, and contract development and manufacturing organization (CDMO) services that support translation of reprogrammed cells into clinical products. Merck KGaA (operating as MilliporeSigma in the U.S.) supplies reagents, kits, and instrument platforms widely used for iPSC derivation and downstream assays. FUJIFILM Cellular Dynamics (part of FUJIFILM) develops and commercializes human iPSC-derived cell lines and related services for drug discovery and cell therapy manufacturing. STEMCELL Technologies focuses on specialized cell culture media, reagents, and instruments tailored to stem cell and reprogramming workflows for academic and industry researchers. REPROCELL markets reprogramming-related cell products and has publicized clinical- and research-grade iPSC offerings and edited iPSC lines for immune-modulated applications. Bio-Techne supplies discovery and cell-culture reagents, assay kits, and protein tools that support reprogramming experiments and characterization. Mogrify offers computational and direct-conversion technologies intended to predict and drive cell fate transitions and partners with industry and academic groups to map conversion factors and accelerate generation of target cell types. Fate Therapeutics concentrates on developing off-the-shelf, engineered cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), advancing reprogrammed-cell platforms toward clinical applications. Takara Bio provides reprogramming kits, gene-delivery tools, and molecular biology reagents used across iPSC generation and manipulation workflows.
These ten companies cover the spectrum from basic reagents and instruments to computational prediction, CDMO manufacturing, and clinical-stage cell therapy development, which together drive commercialization and application of reprogramming technologies. Market analyses and industry reports list Thermo Fisher, Lonza, Merck KGaA, FUJIFILM Cellular Dynamics, STEMCELL Technologies, REPROCELL, Bio-Techne, Mogrify, Fate Therapeutics, and Takara Bio among leading players in the cell reprogramming market, noting their roles in supplying reagents, platforms, iPSC lines, manufacturing capacity, predictive software, and therapeutic pipelines that underpin research and clinical translation. Recent coverage highlights strategic collaborations, CDMO capacity expansions, AI and computational tool adoption, and product launches as factors strengthening these companies’ positions in a market projected to grow substantially over the coming decade.
Investments, partnerships, and product diversification by these firms reflect shifting priorities in the reprogramming ecosystem—scalability, regulatory-grade manufacturing, automation, and integration of computational and AI-driven selection of reprogramming factors—all aimed at reducing cost, increasing reproducibility, and enabling clinical translation of reprogrammed-cell products. Market reports and industry summaries emphasize that North America and Asia-Pacific remain key regions for demand and innovation, while company-specific moves such as FUJIFILM’s life-science expansions, Lonza’s capacity additions, and collaborative platforms for clinical-grade iPSC supply illustrate how these ten organizations are consolidating technical and manufacturing capabilities to meet rising research and therapeutic needs.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell reprogramming by geography and historical trend. The scope of the report extends to sizing of the cell reprogramming market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Thermo Fisher Scientific, Lonza, Merck KGaA (MilliporeSigma), FUJIFILM Cellular Dynamics, STEMCELL Technologies, REPROCELL, Bio-Techne, Mogrify, Fate Therapeutics, and Takara Bio represent ten major companies active in cell reprogramming, each supplying critical products, platforms, or therapeutic pipelines that shape the field. Thermo Fisher offers broad reagent, instrument, and platform portfolios used in reprogramming research and manufacturing. Lonza provides large-scale manufacturing, media, and contract development and manufacturing organization (CDMO) services that support translation of reprogrammed cells into clinical products. Merck KGaA (operating as MilliporeSigma in the U.S.) supplies reagents, kits, and instrument platforms widely used for iPSC derivation and downstream assays. FUJIFILM Cellular Dynamics (part of FUJIFILM) develops and commercializes human iPSC-derived cell lines and related services for drug discovery and cell therapy manufacturing. STEMCELL Technologies focuses on specialized cell culture media, reagents, and instruments tailored to stem cell and reprogramming workflows for academic and industry researchers. REPROCELL markets reprogramming-related cell products and has publicized clinical- and research-grade iPSC offerings and edited iPSC lines for immune-modulated applications. Bio-Techne supplies discovery and cell-culture reagents, assay kits, and protein tools that support reprogramming experiments and characterization. Mogrify offers computational and direct-conversion technologies intended to predict and drive cell fate transitions and partners with industry and academic groups to map conversion factors and accelerate generation of target cell types. Fate Therapeutics concentrates on developing off-the-shelf, engineered cellular immunotherapies derived from induced pluripotent stem cells (iPSCs), advancing reprogrammed-cell platforms toward clinical applications. Takara Bio provides reprogramming kits, gene-delivery tools, and molecular biology reagents used across iPSC generation and manipulation workflows.
These ten companies cover the spectrum from basic reagents and instruments to computational prediction, CDMO manufacturing, and clinical-stage cell therapy development, which together drive commercialization and application of reprogramming technologies. Market analyses and industry reports list Thermo Fisher, Lonza, Merck KGaA, FUJIFILM Cellular Dynamics, STEMCELL Technologies, REPROCELL, Bio-Techne, Mogrify, Fate Therapeutics, and Takara Bio among leading players in the cell reprogramming market, noting their roles in supplying reagents, platforms, iPSC lines, manufacturing capacity, predictive software, and therapeutic pipelines that underpin research and clinical translation. Recent coverage highlights strategic collaborations, CDMO capacity expansions, AI and computational tool adoption, and product launches as factors strengthening these companies’ positions in a market projected to grow substantially over the coming decade.
Investments, partnerships, and product diversification by these firms reflect shifting priorities in the reprogramming ecosystem—scalability, regulatory-grade manufacturing, automation, and integration of computational and AI-driven selection of reprogramming factors—all aimed at reducing cost, increasing reproducibility, and enabling clinical translation of reprogrammed-cell products. Market reports and industry summaries emphasize that North America and Asia-Pacific remain key regions for demand and innovation, while company-specific moves such as FUJIFILM’s life-science expansions, Lonza’s capacity additions, and collaborative platforms for clinical-grade iPSC supply illustrate how these ten organizations are consolidating technical and manufacturing capabilities to meet rising research and therapeutic needs.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.